Sign Up

Have an account?

Sign In

Don't have account,

Forget Password

Lost your password? Please enter your email address. You will receive a link and will create a new password via email.

Have an account?

Please type your username.

Please type your E-Mail.

Please choose an appropriate title for the question so it can be answered easier.

Please choose the appropriate section so question can be searched easier.

Please choose suitable Keywords Ex: question, poll.

Type the description thoroughly and in details.

Choose from here the video type.

Put here the video id : https://www.youtube.com/watch?v=sdUUx5FdySs Ex: 'sdUUx5FdySs'.

Captcha Click on image to update the captcha.

Search
Ask a Question

Home / Questions / Q 242708
Next
In Process
H.P.Dubey

H.P.Dubey

View Profile
  • 4
Asked: In:

Why India cancelled a patent granted to GlaxoSmith Kline PLC for its breast cancer drug Tykerb on 1 August 2013.

  • 4
Share

1 Answer

  1. eAnswers Team

    View Profile
    Added an answer on August 3, 2018 at 6:31 am

    India has revoked a patent granted to GlaxoSmithKline Plc’s breast cancer drug Tykerb, the drug is a salt form of the original compound, lapatinib. According to Indian authorities they didn’t find GlaxoSmithKline PLC’s drug Tykerb provided “enhanced therapeutic efficacy” over the underlying patented drug Lapatinib.
    TO read more :- http://online.wsj.com/article/SB10001424127887324635904578644100746473088.html

    • 0

Leave an answer